Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX – Get Rating) was the target of a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 38,300 shares, a drop of 41.1% from the June 30th total of 65,000 shares. Currently, 0.5% of the company’s shares are short sold. Based on an average daily volume of 145,500 shares, the short-interest ratio is presently 0.3 days.
Virpax Pharmaceuticals Price Performance
VRPX stock opened at $1.52 on Friday. The stock has a 50-day moving average price of $1.53 and a 200-day moving average price of $1.87. Virpax Pharmaceuticals has a 1-year low of $1.19 and a 1-year high of $36.00.
Insider Buying and Selling
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. Citigroup Inc. acquired a new stake in shares of Virpax Pharmaceuticals in the 1st quarter valued at about $27,000. Warberg Asset Management LLC acquired a new stake in shares of Virpax Pharmaceuticals in the 1st quarter valued at about $39,000. Vanguard Group Inc. grew its stake in shares of Virpax Pharmaceuticals by 4.5% in the 1st quarter. Vanguard Group Inc. now owns 341,977 shares of the company’s stock valued at $759,000 after buying an additional 14,672 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in shares of Virpax Pharmaceuticals in the 1st quarter valued at about $348,000. 18.90% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Separately, Maxim Group initiated coverage on Virpax Pharmaceuticals in a research report on Thursday, June 9th. They set a “buy” rating and a $4.00 target price for the company.
Virpax Pharmaceuticals Company Profile
Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
- Get a free copy of the StockNews.com research report on Virpax Pharmaceuticals (VRPX)
- Procter’s Earnings Start To Show Weakness In Q4
- MarketBeat: Week in Review 7/25 – 7/29
- The One Question You Have to Ask Before Investing in INTC Stock
- Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
- Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
Receive News & Ratings for Virpax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virpax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.